Igor Štagljar

Dr. Igor Stagljar is a world-renowned scientist and a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre, University of Toronto, Canada.

He is also a Laboratory Head at the Mediterranean Institute of Life Sciences, Split, Croatia.

He is a recognized expert in the field of protein-protein interactions (PPIs) and PPI technology development. He has published over 119 research papers listed on PubMed, is the holder of 6 patents, and has been honored as one of the top inventors in Canada. His visionary leadership has led to development of the Membrane Yeast Two-Hybrid (MYTH) and Mammalian Membrane Two-Hybrid (MaMTH) technologies, both of which have revolutionized membrane PPI research. During his entire career he has been an innovator, and his most recent development of MaMTH into a drug screening platform (MaMTH-DS) as well as the SIMPL technology has the potential to dramatically improve the development of therapeutics against membrane (MaMTH-DS) and soluble (SIMPL) PPI targets.

He is currently directing major proteomics projects to map how integral membrane proteins interact to produce either healthy or diseased cells, to identify novel membrane PPI therapeutic targets, and to screen for novel drugs, in particular to target lung cancer. Dr. Stagljar works tirelessly with leading clinicians and scientists worldwide to advance research on health issues such as cancer.

Dr. Stagljar has co-founded two companies, Dualsystems Biotech Inc., a world-leading company in the field of interactive proteomics, and two new Toronto-based biotech start-up companies named ProteinNetwork Therapeutix, Inc and Perturbo Inc.